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Human cytomegalovirus (HCMV) infection causes a rapid induction of c-Fos and c-Jun, the major subunits
of activator protein 1 (AP-1), which in turn have been postulated to activate the viral immediate-early (IE)
genes. Accordingly, the major IE promoter (MIEP) enhancer, a critical control region for initiating lytic HCMV
infection and reactivation from the latent state, contains one well-characterized AP-1 site and a second
candidate interaction site. In this study we explored the role of these AP-1 elements in the context of the
infection. We first show that the distal candidate AP-1 motif binds c-Fos/c-Jun heterodimers (AP-1 complex)
and confers c-Fos/c-Jun-mediated activity to a core promoter. Site-directed mutagenesis studies indicate that
both AP-1 response elements are critical for 12-O-tetradecanoylphorbol-13-acetate (TPA)-enhanced MIEP
activity in transient-transfection assays. In marked contrast to the results obtained with the isolated promoter,
disruption of the AP-1 recognition sites of the MIEP in the context of the infectious HCMV genome has no
significant influence on the expression of the MIE protein IE1 or viral replication in different cell types.
Moreover, a chimeric murine CMV driven by the HCMV MIEP (hMCMV-ES) with the two AP-1 binding sites
mutated is not compromised in virulence, is able to grow and disseminate to different organs of the newborn
mice as efficiently as the parental virus, and is competent in reactivation. We show, however, that combined
inactivation of the enhancer AP-1 and NF-B recognition sites leads to an attenuation of the hMCMV-ES in
the neonatal murine infection model, not observed when each single element is abolished. Altogether, these
results underline the functional redundancy of the MIEP elements, highlighting the plasticity of this region,
which probably evolved to ensure maximal transcriptional performance across many diverse environments.
Human cytomegalovirus (HCMV) replication begins with
the expression of the major immediate-early (MIE) gene prod-
ucts IE1 and IE2, which are multifunctional proteins mainly
involved in regulating both viral and cellular gene expression
(reviewed in reference 51). The MIE proteins are essential for
the progression of the replication cycle and crucial determi-
nants of the transition from latency to reactivation (62, 63).
Hence, the regulation of their expression is a key point in
controlling the outcome of the HCMV infectious programs.
Transcription of the HCMV MIE genes is driven by a com-
plex and potent promoter, the MIE promoter (MIEP), which
comprises different functional units including a basal pro-
moter, the enhancer region, and the modulator (23). The
MIEP contains binding sites for a diverse set of signal-regu-
lated stimulatory and inhibitory transcription factors, such as
NF-B, ATF/CREB, activator protein 1 (AP-1), YY1, Sp1/
Sp3, and retinoic acid receptor (RAR)/retinoid X receptor
(RXR), most of them densely packed in the enhancer region
(48). In addition, viral tegument proteins and the MIE proteins
themselves have also been shown to modulate MIEP activity.
During latency, the MIEP is associated with markers of re-
pressed heterochromatin, remaining silent (53, 59). Cellular
differentiation and alterations in the levels of specific transcrip-
tion factors by a variety of stimuli promote the activation of the
MIEP and thereby the expression of downstream MIE genes.
Consequently, MIEP activity is dependent on cell type, cellular
differentiation stage, and the activity of specific signaling trans-
duction pathways. Work with transgenic mice carrying a LacZ
reporter under the control of the HCMV MIEP enhancer
indicated that the expression of the MIEP is restricted to
specific cell types in multiple organs, paralleling tissues nor-
mally infected by HCMV in the natural host (5, 6, 41). A
number of studies in the last several years have addressed the
relevance of different segments of the MIEP for MIE gene
expression and viral replication (27, 33, 34, 47, 49). While the
more distal component of the enhancer (spanning from 550
to 300 relative to the transcription start site [1] of the
MIEP) has been shown only to partially contribute to viral
replication at a low multiplicity of infection (MOI) (47), pro-
gressive deletions starting from the distal end of the proximal
segment of the enhancer (spanning from 300 to 39) re-
sulted in recombinant viruses that replicated slower and with
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more-reduced efficiencies (33). Notably, HCMVs with the
complete enhancer region eliminated fail to replicate in cul-
tured fibroblasts (27), demonstrating a crucial genetic role for
this regulatory region. The contribution of a number of binding
sites for cellular transcription factors in the enhancer has been
extensively assessed in cell reporter assays and shown to affect
promoter function, and more recently in specific cases, the
roles of particular sites have been examined in the context of
infection (7, 16, 17, 27, 32, 37, 38, 43, 46, 55). However, due to
the strict species specificity associated with HCMV, the impact
of disrupting enhancer elements in a natural infection cannot
be approached. Thus, we are still far from understanding the
mechanisms of action of the MIEP in vivo.
In the related mouse cytomegalovirus (MCMV), we showed
that enhancerless viruses are viable but exhibit an MOI-depen-
dent growth phenotype in permissive fibroblasts. Most impor-
tantly, these enhancer-deficient viruses are drastically attenu-
ated even in immunocompromised SCID mice (24). In fact, we
have recently reported that enhancerless MCMVs are capable
of establishing a low-level maintenance infection but fail to
grow exponentially in tissues of the severely immunodeficient
host (56). These results demonstrate a key role of the enhancer
in viral multiplication and pathogenesis in its natural host.
Although the MIEPs diverge across CMV species in complex-
ity, number, and distribution of transcription factor binding
sites and in the primary sequence, they are conserved at the
functional level and share several common regulatory elements
(15, 19, 63). On this basis, and to investigate the regulation of
the HCMV MIEP in latency and pathogenesis, infectious
model systems were developed based on chimeric MCMVs in
which the native MIEP enhancer, with or without the core
promoter, was replaced by the corresponding region from
HCMV (4, 25, 26). These hybrid viruses are highly competent
to grow in permissive fibroblasts but exhibit a partial defect in
dissemination and replication in specific organs during acute
infection. To get around this limitation, we have recently used
the neonatal mouse model and established conditions of infec-
tion for the enhancer swap virus (hMCMV-ES) that mostly
reproduce the in vivo growth characteristics and latency/reac-
tivation properties of wild-type (wt) MCMV (26). Thus, this
system allows us now to analyze the involvement of specific
genetic elements of the HCMV enhancer in tissue tropism and
pathogenesis and, for the first time, in the establishment of
latency and subsequent reactivation.
The AP-1 family of transcription factors participates in the
regulation of multiple genes involved in control of cell prolif-
eration, differentiation, apoptosis, immune responses, and tu-
morigenesis in response to a wide array of stimuli, including
stress, growth factors, and proinflammatory cytokines (20).
AP-1 is a dimeric transcription factor that includes members of
the Jun (c-Jun, JunB, and JunD) and Fos (c-Fos, FosB, Fra-1,
and Fra-2) families (2), which form homo- and heterodimers
that bind and activate transcription at 12-O-tetradecanoylphor-
bol-13-acetate (TPA) response elements (TRE) with the con-
sensus sequence 5-TGAC/GTCA-3 (3; reviewed in reference
60). Some DNA viruses have developed different strategies to
manipulate AP-1, most likely destined to enhance viral repli-
cation, and several lines of evidence indicate that this could be
the case for HCMV. Early studies demonstrated that HCMV
induces AP-1 in a biphasic mode. The initial interaction of viral
particles with the cell leads to a rapid induction of both c-Fos
and c-Jun (8–10), the major components of AP-1, and later in
the infection a second increase of c-Fos RNA, in which the
viral IE1 and IE2 proteins have been involved, can be observed
(28, 52). Furthermore, in independent studies using transfec-
tion assays, IE1 has been reported to stimulate AP-1 activity,
mainly through c-Jun phosphorylation by c-Jun N-terminal
kinase (39, 65). In addition, the MIEP enhancer region dis-
plays a consensus AP-1 element between positions 174 and
168 (relative to the transcription start site [1] of the
MIEP), which has been previously shown to be important for
promoter activity in transient-transfection assays (44) but re-
cently reported not to substantially contribute to viral replica-
tion in vitro (17), and a potential nonconsensus AP-1 motif
between positions 239 and 233, which remains unexplored.
The virion pp71 protein has been reported to strongly stimu-
late transcription from promoters with ATF/CREB and AP-1
elements, including the MIEP (45). Moreover, besides the
proposed positive role of AP-1 in HCMV replication, AP-1 has
also been implicated in viral reactivation. Work by Hummel
and Abecassis (30) in the mouse model provided evidence that
allogeneic transplantation induces activation of AP-1, which in
turn could stimulate MCMV IE1 gene expression, the first step
required in viral reactivation. Notably, the MCMV enhancer
harbors several scattered AP-1 sites (19). In addition, using the
HCMV MIEP enhancer transgenic mouse model, signaling
mediated by ischemia/reperfusion injury has been shown to
contribute to the activation of the HCMV enhancer most likely
through stimulation of AP-1 (40).
In the present study, we have sought to directly test the role
of the AP-1 motifs in the HCMV enhancer during a CMV
infection, both in tissue culture and in a mouse model.
Through the generation and use of HCMV and MCMV en-
hancer swap recombinants containing mutations in the AP-1
response elements of the MIEP enhancer, we show that dis-
ruption of these sites has neutral effects on MIE gene expres-
sion or viral replication in culture cells and does not lead to
reduced viral growth and dissemination among different or-
gans or altered mortality in mice. Moreover, the mutated en-
hancer swap virus is not notably impaired in its reactivation
capacity. We report, however, that simultaneous elimination of
the enhancer AP-1 and NF-B recognition sites results in re-
duced growth of the enhancer swap virus during acute infec-
tion. Thus, altogether our results demonstrating the dispens-
ability of the enhancer AP-1 binding motifs in the infectious
life cycle of CMV and its in vivo compensation through the
NF-B elements evidence the functional robustness of the
MIEP regulation by host factors.
MATERIALS AND METHODS
Cells and viruses. The human lung fibroblast cell line HEL299, the U373 MG
cell line derived from glioblastoma, the endothelial cell line SVEC-4, the epi-
thelial tumor cell line C127I, the macrophagic cell line RAW 264.7, and primary
mouse embryonic fibroblasts (MEFs) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 2 mM glutamine, 1 mM sodium
pyruvate, 50 U of penicillin per ml, 50 g of streptomycin per ml, and 10% fetal
bovine serum (FBS). The myelomonocytic U937 cells were cultured in RPMI
1640 medium supplemented as stated above and 10% FBS. The retinal pigment
epithelium (RPE) cells were grown in DMEM–Ham’s F-12 (1:1) medium sup-
plemented with 2 mM glutamine, 50 U of penicillin per ml, 50 g of streptomycin
per ml, 0.25% sodium bicarbonate, and 5% FBS. The murine liver-derived cell
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line MMH (1) was cultured on collagen-coated plates in RPMI 1640 medium
supplemented with 2 mM glutamine, 50 U of penicillin per ml, 50 g of strep-
tomycin per ml, 100 ng/ml of epidermal growth factor, 16 ng/ml of insulin-like
growth factor II, 10 g/ml of insulin, and 10% FBS. The parental HCMV strain
used in this study is the recombinant virus HCMV-GFP (green fluorescent
protein) (11) originating from the bacterial artificial chromosome (BAC)-cloned
HCMV AD169 genome (14). The parental hMCMV-ES, a chimeric MCMV in
which the natural enhancer (sequences from nucleotides [nt] 48 to 1191) has
been replaced by the HCMV enhancer (sequences from 52 to 667), was
generated from a full-length MCMV Smith-BAC (pSM3fr) (64) as described in
the work of Gustems et al. (26). The enhancerless MCMV, MCMVdE, and
the enhancer swap MCMV containing the enhancer NF-B sites disrupted,
hMCMV-ES.NFkB, have been previously described (7, 24). Viral stocks were
prepared by infecting cells at a low MOI and titrated by standard plaque assays
on HEL299 cells (HCMV-derived stocks), MEFs, or NIH 3T3-Bam25 cells (24)
(hMCMV-ES-derived stocks).
Plasmid construction. The reporter plasmid pMIEP(66/7)CAT, which en-
compasses MIEP sequences between nucleotide positions 66 and 7 in front
of the chloramphenicol acetyltransferase (CAT) reporter gene, has been de-
scribed previously (22). This construct essentially contains the MIEP TATA and
cis repression sequence (crs) element but lacks the upstream enhancer and
downstream transcriptional control domains. The reporter plasmid pMIEP(66/
7)2Ap1CAT was generated by inserting two copies of the double-stranded
oligonucleotides 5-GTA TTA GTC ATC GCT ATT ACC ATG-3 and 5-CAT
GGT AAT AGC GAT GAC TAA TAC-3, corresponding to the AP-1239
recognition site and flanking natural sequences, at the HindIII site of the
pMIEP(66/7)CAT. The reporter constructs pMIEP.Luc, pMIEPAp1239.Luc,
pMIEPAp1239/174.Luc, and pMIEPNFkB.Luc contain the luciferase gene un-
der the control of wild-type (wt) MIEP sequences from 1145 to 112 or these
same sequences containing mutations in the AP-1239, both AP-1239 and AP-
1174 (see Fig. 2A), or NF-B (27) binding sites, respectively. Plasmids
pMIEP(1145/112)CAT.Ap1 and pIE111H.Ap1 were generated by disrupting
through site-directed mutagenesis the two AP-1 elements in the HCMV MIEP
enhancer in pMIEP(1145/112)CAT (21) and pIE111H (4), respectively. To
generate the shuttle plasmid pST76-AsacB.MIEP.Ap1, the 2.1-kbp MluI frag-
ment from pIE111H.Ap1 was transferred into pST76-ASacB as described in the
work of Benedict et al. (7). Plasmid pST-SNRNsi is a shuttle plasmid contain-
ing the HCMV MIEP enhancer (from nt 52 to nt 667) flanked by sequences
from nt 178699 to nt 182940 and from nt 184086 to nt 187889 of the MCMV
genome (58) and where an NsiI site (originally introduced during hMCMV-ES
generation) (4) between the HCMV MIEP position667 and the MCMV MIEP
position 1192 (nt 184086 of the MCMV genome) has been disrupted by site-
directed mutagenesis. The shuttle plasmid pST-ES.NFkB/Ap1 was constructed
by replacing in pST-SNRNsi a 630-bp NotI/BlpI fragment, including HCMV
MIEP sequences from nt 52 to nt 667, with the same enhancer sequences
containing the two AP-1 and the four NF-B binding sites mutated, previously
obtained by site-directed mutagenesis. The identities of all recombinant plasmids
were confirmed by DNA sequencing.
Transfection assays. Transfections of U373 cells and MEFs were performed
by the calcium phosphate coprecipitation method as described previously (22),
while U937 cells were electroporated (960 F, 200 V). Cellular extracts were
prepared and assayed for -galactosidase, luciferase, or CAT activity (22). Equal
final concentrations of transfected DNA were achieved with pUC19 plasmid.
pSV-c-jun expression clone and pBK28 (human c-Fos cDNA expression vector)
were a gift from I. Verma (The Salk Institute, California). For the CAT assays,
cell extracts containing the same amount of -galactosidase were used. The CAT
activity was quantified by liquid scintillation counting. Luciferase activity was
measured with the dual-luciferase reporter assay system (Promega) according to
the manufacturer’s instructions. Firefly luciferase activities in lysates were nor-
malized using the corresponding internal Renilla luciferase activities (provided
by the tk-Renilla plasmid pRL-TK).
Generation of CMV mutants. HCMV.Ap1 mutants were generated starting
from the HCMV-GFP BAC (11), which contains the enhanced GFP (E-GFP)
open reading frame under the control of the MCMV MIEP inserted within the
US2-US11 region, by using two sequential ET mutagenesis steps (13, 54). First,
enhancer sequences from 52 to 667 were replaced by the rpsL-neo cassette
amplified from plasmid pRpsL-neo (Gene Bridges, Germany) with oligonucle-
otides Henh-rpsl.for (5-CAC TAA ACG AGC TCT GCT TAT ATA GAC CTC
CCA CCG TAC ACG CCT GGC CTG GTG ATG ATG GCG GGA TC-3) and
Henh-rpsl.rev (5-CAT TGG TTA TAT AGC ATA AAT CAA TAT TGG CTA
TTG GCC ATA TCA GAA GAA CTC GTC AAG AAG G-3). In the second
step, the enhancer sequences were reintroduced using the linear MluI/EagI
fragment from plasmid pMIEP(1145/112)CAT.Ap1. Two independent BACs
were obtained and called HCMV.Ap1a and HCMV.Ap1b. The hMCMV-
ES.Ap1 BAC and hMCMV-ES.NFkB/Ap1 BAC were generated by the two-step
mutagenesis procedure as described in the work of Benedict et al. (7) using
MCMV pSM3fr BAC and shuttle plasmid pST76-AsacB.MIEP.Ap1 or pST-
ES.NFkB/Ap1, respectively. To construct hMCMV-ES.Ap1-rev, first the en-
hancer sequences from 52 to 667 were deleted by ET mutagenesis using a
linear fragment amplified from plasmid pGP704-kan (13) with oligonucleotides
EnhBLPIdel.for (5-GTA CCG ACG CTG GTC GCG CCT CTT ATA CCC
ACG TAG AAC GCA GCT CAG CAG GAC GAC GAC GAC AAG TAA-3)
and EnhNDEIdel.rev (5-GAC TTT TTA CCC AAT TTC CCA AGC GGA
AAG CCC CCT AAT ACA CTC ATA TGA CAG GAA CAC TTA ACG GCT
GA-3). Then the enhancer sequences were reintroduced by the two-step mu-
tagenesis procedure using the shuttle plasmid pST-SNRNsi. The resulting BAC
was called hMCMV-ES.Ap1-rev and is identical to parental hMCMV-ES, except
that it lacks an NsiI site adjacent to the HCMV MIEP enhancer. To generate
hMCMV-ES.NFkB/Ap1-rev, first the enhancer sequences from 52 to 667
were deleted by ET mutagenesis using a linear fragment amplified from plasmid
pOri6K-F5 (12) with oligonucleotides MMIEPK6.for (5-GCG GAA AGC CCC
CTA ATA CAC TCA TAA AAT GCA TAA AGC GGC CGC GAA AAG TGC
CAC CTG CAG AT-3) and MMIEPK6.rev (5-CGA CGC TGG TCG CGC
CTC TTA TAC CCA CGT AGA ACG CAG CTC AGC CAG GAA CAC TTA
ACG GCT GA-3). Then the enhancer sequences were reintroduced as indi-
cated in the construction of hMCMV-ES.Ap1-rev, resulting in an hMCMV-
ES.NFkB/Ap1-rev BAC identical to parental hMCMV-ES except that the NsiI
site adjacent to the HCMV MIEP enhancer is absent. BACs were transfected
into HEL299 cells (HCMVs) or MEFs (hMCMV-ESs) using the calcium phos-
phate transfection technique. Progeny virus obtained from the transfections were
amplified, subjected to three rounds of plaque purification, and used for the
preparation of viral stocks. The integrity of the viruses generated was confirmed
by restriction enzyme analysis, and enhancer regions were sequenced (data not
shown). Enhancer sequences were as expected for all the recombinants, except in
hMCMV-ES.Ap1, where sequences between 607 and 602 in the MIEP en-
hancer were CGCCAT instead of GGTACG.
Mobility shift assays. The mobility shift assay was performed essentially as
described previously (22). Probe MIEP-239, containing the AP-1 element at
position239, consisted of double-stranded oligonucleotides 5-GTA TTA GTC
ATC GCT ATT ACC ATG-3 and 5-CAT GGA AAT AGC GAT GAC TAA
TAC-3. Probe AP-1cons, containing a consensus AP-1 motif, consisted of oligo-
nucleotides 5-AGC TTA GCT ATG ACT CAT CCG GAA GCT-3 and 5-
AGC TTC CGG ATG AGT CAT AGC TAA GCT-3. The probe bearing the
AP1174 site consisted of oligonucleotides 5-GAT AGC GGT TTG ACT CAC
GGG GAT-3 and 5-ATC CCC GAG AGT CAA ACC GCT ATC-3. The
probe containing the NF-B motif consisted of oligonucleotides 5-ATG TGA
GGG GAC TTT CC C AGG C-3 and 5-GCC TGG GAA AGT CCC CTC
AAC T-3. For in vitro transcription of RNA for c-Jun and c-Fos, RNA was
synthesized from linearized pGEM-cjun and pGEM-cfos plasmids using T7
RNA polymerase and a standard in vitro transcription protocol. In vitro-tran-
scribed RNA (50 l) for each transcript was mixed with 60 l of rabbit reticu-
locyte lysate (Amersham). The reaction volume was adjusted to 150 l (depend-
ing on single or cotranslation mixtures) and incubated at 30°C for 1 h. The c-Fos
and c-Jun proteins were preincubated in binding buffer either independently, in
combination, or as cotranslation products at room temperature for 15 min, and
subsequently the 32P-labeled oligonucleotide probes were added to the reaction
mixtures and further incubated at room temperature for 30 min. To get first-
order kinetics of binding, labeled oligonucleotide probes in the reaction mixtures
were added in excess. Reaction mixtures were analyzed on 4% polyacrylamide
gels. After electrophoresis, the gel was dried and autoradiographed.
Viral nucleic acid isolation and analysis. Preparation of total DNA from
infected cells, restriction analysis, and gel electrophoresis were essentially done
as described previously (4). BAC DNA was prepared by the alkaline lysis pro-
cedure (13). To analyze whether an appropriate excision of the BAC vector
sequences from the recombinant hMCMV-ES genomes had occurred, PCRs
were performed as described previously (64) using genomic DNA isolated either
from cells infected with the recombinant viruses or from the full-length MCMV
BAC (data not shown). To confirm the correct mutagenesis of the AP-1 binding
sites of the MIEP enhancer in HCMV.Ap1 and hMCMV-ES.Ap1 recombinants,
enhancer sequences were amplified with primers dN and dBlp (7) from viral
stocks by PCR and the amplified fragments were subjected to endonuclease
treatment with ApaI or BglII. Appropriate disruption of the MIEP NF-B
binding sites in hMCMV-ES.NFkB, or both NF-B and AP-1 binding elements
in hMCMV-ES.NFkB/Ap1, was verified by PCR amplification of enhancer se-
quences from viral stocks using primers M182 (5-GAC GGT ACC GAC GCT
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GGT-3) and AA3 (5-CTG GCT CTC CGC CCA AGG GCC CCC GCC C-3)
and subsequent treatment with StuI and ApaI endonucleases.
Determination of CMV replication kinetics. Multistep growth in vitro was
analyzed by infecting different cell types in 24-well plates with the recombinant
viruses at the indicated multiplicities of infection. MMH cells were treated for 10
days before infection with 2% dimethyl sulfoxide (DMSO). After a 2-h adsorp-
tion period, cells were washed with phosphate-buffered saline (PBS) and incu-
bated in DMEM supplemented with 3% FBS. At specific time points postinfec-
tion (p.i.), the supernatants of the infected cells were harvested, cleared of
cellular debris, and frozen at70°C. Infectious virus was determined by standard
plaque assay on MEFs (recombinant hMCMV-ESs) or HEL299 cells (recombi-
nant HCMVs). In the case of U373 cells, intracellular viral titers were measured.
For the growth kinetics assays performed under starvation conditions, cells were
cultured in medium containing 0.5% FBS from 24 h before the infection and
until the end of the experiment. 12-O-Tetradecanoylphorbol-13-acetate (TPA) at
20 ng/ml or the corresponding vehicle (DMSO) was added to the culture medium
containing 0.5% FBS 2 h before infection and maintained until the end of the
experiment.
Western blot analysis. HEL299 cells were either mock infected or infected
with parental or mutant HCMVs at the different MOIs indicated. In specific
cases, cells were also treated with TPA as indicated above. At 6, 12, 24, 48, and
72 h p.i., samples were lysed in protein sample buffer and boiled for 5 min. Cell
lysates were subjected to SDS-PAGE (7% polyacrylamide) and transferred to
nitrocellulose filters. Equal quantities of total protein were analyzed per lane.
Filters were incubated with anti-HCMV IE1 or anti--actin specific monoclonal
antibodies, MAB810 (Chemicon) and A2066 (Sigma), respectively. As secondary
antibodies, horseradish peroxidase-conjugated goat anti-mouse immunoglobulin
G (W402B; Promega) or peroxidase-conjugated goat anti-rabbit immunoglobu-
lin G (111-035-003; Jackson) was used. Blots were developed by using the
Immuno-Star horseradish peroxidase (HRP) substrate (Bio-Rad) according to
the manufacturer’s protocol.
Mouse infections. Three-day-old BALB/cOlaHsd mice were obtained from
Harlan (Netherlands) and housed in the vivarium (University of Barcelona)
under specific-pathogen-free conditions. To assess levels of virulence, 3-day-old
BALB/c mice were inoculated intraperitoneally (i.p.) with increasing doses of
tissue culture-derived hMCMV-ES recombinants (ranging from 1  103 to 2 
106 PFU per mouse in a final volume of 40 l) and their survival was monitored
daily for at least 40 days after infection. Data points were fitted to a sigmoidal
function available at Origin software, and the 50% lethal dose (LD50) values
were estimated from these curves. To analyze the replication of the hMCMV-ES
recombinants in vivo, mice were i.p. inoculated with 5  104 PFU of tissue
culture-propagated virus. At designated times after infection, mice were sacri-
ficed, and specific organs were removed and harvested as a 10% (wt/vol) tissue
homogenate. Tissue homogenates were sonicated and centrifuged, and viral
titers from the supernatants were determined by standard plaque assays, includ-
ing centrifugal enhancement of infectivity (29) on MEFs. An ex vivo assay was
utilized to detect reactivated virus from spleen and lung, as previously described
(35, 57). Briefly, mice were i.p. inoculated with 5  104 PFU of tissue culture-
derived hMCMV-ES recombinants and maintained for 4 months to establish
latency. Animals were sacrificed, and their spleens, lungs, and salivary glands
were harvested. Reactivation was examined from spleens and lungs, which were
manually minced and placed with medium in wells of a six-well multiwell plate.
Cultures were kept (with fresh medium addition when required) for 50 days.
Every 5 days, part of the supernatant was transferred to MEF monolayers
(including a centrifugal-enhancement-of-infectivity step) for detection of infec-
tious virus. The identity of the reactivated viruses was confirmed by PCR analysis
using two primers that bind to viral sequences flanking the MCMV enhancer and
as templates viral DNAs from the indicator MEF cultures when cytopathic effect
was reached (shown in Fig. S1 in the supplemental material). In addition, PCR
products from a representative sample of each group and organ were cloned and
sequenced. Salivary glands were analyzed to ensure the clearance of infectious
virus at the time of explantation, by sonicating them as a 10% (wt/vol) tissue
homogenate and subsequently transferring them to MEF monolayers.
RESULTS
Characterization of the AP-1239 binding site in the HCMV
MIEP. In addition to the already-described AP-1 recognition
motif (44) (referred to here as AP-1174) located from nt174
to 168 (relative to the ie1/ie2 transcription start site), the
MIEP enhancer harbors another putative binding site for AP-1
situated from nt 239 to 233 (referred to here as AP-1239)
that remains unexplored. While the AP-1174 motif
(TGACTCA) is a perfect match to the AP-1 consensus se-
quence (TGAC/GTCA), the AP-1239 element (TTAGTCA)
differs in 1 nucleotide from it. We sought to examine the ability
of c-Jun and c-Fos to directly bind to this AP-1239 motif by
performing electrophoretic mobility shift assays (EMSAs) us-
ing a radiolabeled oligonucleotide probe containing the poten-
tial AP-1239 recognition sequence (MIEP-239 probe). As a
control, we carried out an EMSA using the consensus se-
quence for AP-1 binding (here named the AP-1cons probe).
As depicted in Fig. 1A, no specific DNA-protein complex was
formed when the radiolabeled MIEP-239 oligonucleotide was
incubated with either c-Fos or c-Jun (lanes 2 and 3). However,
a retarded complex was observed when the MIEP-239 probe
was incubated with both combined c-Fos and c-Jun (lane 4) or
cotranslated AP-1 complex (lane 5). This complex had a mo-
bility similar to that obtained when c-Fos and c-Jun were in-
cubated with the AP-1cons oligonucleotide (lane 6). To verify
the specificity of the AP-1 binding to the MIEP motif, we first
performed competition assays using excess unlabeled AP-
1cons probe, MIEP-239 probe, a probe containing the AP-
1174 sequence (probe c), or a nonspecific probe containing an
NF-B binding site (probe d). As expected, specific competi-
tion with the AP-1cons probe (lane 7), the MIEP-239 probe
(lane 8), and the probe bearing the AP-1174 motif (lane 9)
abolished the formation of the DNA-protein complex, while
the nonspecific probe did not alter the retarded complex (lane
10). In additional experiments we also performed supershift
assays with anti-c-Jun, resulting in a decreased mobility of the
retarded DNA-protein complex (data not shown). In conclu-
sion, the results indicate that c-Jun and c-Fos proteins interact
with the MIEP AP-1239 element.
To analyze whether this element could confer c-Jun and
c-Fos inducibility on a basal promoter, two copies of the AP-
1239 oligonucleotide bearing the distal AP-1 site were in-
serted in a recombinant plasmid, pMIEP(66/7)CAT, con-
taining the core MIEP (comprising sequences between
nucleotide positions 66 and 7) linked to the CAT reporter
gene. In this construct, named pMIEP(66/7)2Ap1CAT,
which essentially contains the TATA and crs element but lacks
the upstream enhancer and downstream transcriptional con-
trol domains, the two copies of the distal AP-1 site were cloned
5 at position 66 of the promoter (Fig. 1B). U373 cells were
transfected with pMIEP(66/7)2Ap1CAT or the control
plasmid pMIEP(66/7)CAT in the presence or absence of
cotransfected c-Fos, c-Jun, or both. In the absence of c-Fos-
and c-Jun-expressing plasmids, low levels of transcriptional
activity from pMIEP(66/7)2Ap1CAT could be detected,
while barely no transcriptional activity was observed from
pMIEP(66/7)CAT under the same conditions (Fig. 1B and
data not shown). As seen in Fig. 1B, when each transcription
factor alone was cotransfected, a significant increase (4-fold in
the presence of c-Jun and 2-fold in the presence of c-Fos) in
CAT activity from pMIEP(66/7)2Ap1CAT was obtained,
but none from the control reporter construct pMIEP(66/
7)CAT. The observed activations most likely resulted from
the association of c-Fos and c-Jun transiently expressed with
their corresponding endogenous heterodimeric partners, c-Jun
and c-Fos. However, simultaneous overexpression of c-Fos
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and c-Jun resulted in substantial activation (8-fold) of
pMIEP(66/7)2Ap1CAT that was not detected with
pMIEP(66/7)CAT. Thus, these results illustrate the
functional involvement of c-Fos and c-Jun in the activation
of the distal MIEP AP-1 site.
Direct involvement of the AP-1 motifs in the activation of
the HCMV MIEP. As a first step to test the functional involve-
ment of the HCMV enhancer AP-1 sites in viral infection,
point mutations (shown in Fig. 2A) were introduced within the
core of the two elements present in the MIEP and analyzed in
transient-transfection assays. We also sought to examine the
individual contribution of the AP-1239 site to MIEP activity.
For this purpose, U937 cells were transfected with plasmids
containing sequences from 1144 to 112 of either the wild-
type MIEP, the MIEP mutated in AP-1239, or the MIEP
mutated in both AP-1174 and AP-1239 fused with the lucif-
erase reporter gene (illustrated in Fig. 2B) and treated with
TPA, an activator of AP-1. As shown in Fig. 2C, disruption of
the AP-1239 site resulted in a significant inhibition of the
TPA-induced levels of luciferase activity (from 25- to 17-fold).
As expected, disruption of both AP-1174 and AP-1239 motifs
of the MIEP led to a further reduction (from 25- to 11-fold) of
the TPA-induced luciferase activity. In none of the cases, how-
ever, was the basal transcription of the MIEP mutated con-
structs altered compared to that of the wild-type MIEP re-
porter construct. The absence of a complete elimination of the
TPA-induced MIEP activity could be due to the fact that other
elements, such as the 4 NF-B sites, which remained intact in
the AP-1 mutated MIEP reporter construct, could be contrib-
uting to this stimulation. Accordingly, when U937 cells were
transfected with an NF-B mutated MIEP reporter plasmid,
the TPA-induced promoter response was significantly de-
creased in comparison to that exhibited by the wild-type
MIEP-driven reporter construct (Fig. 2B and D). To further
explore whether these observations could be extended to mu-
rine cells, transfection assays were carried out in MEFs. As
shown in Fig. 2E, mutation of either the AP-1 or NF-B ele-
ment of the MIEP resulted in decreased TPA-induced lucifer-
ase activity, indicating that the AP-1 elements within the
HCMV enhancer are functionally competent in murine cells.
These data are consistent with previous observations reporting
a reduction in lipopolysaccharide (LPS)-induced MIEP activity
after abrogation of the AP-1174 element in RAW 264.7 cells,
although in this case a slight reduction of basal MIEP activity
FIG. 1. The AP-1239 motif of the HCMV MIEP binds c-Jun/c-Fos heterodimers and confers c-Jun/c-Fos-mediated responsiveness. (A) Mo-
bility shift assay demonstrating the interaction of c-Jun/c-Fos heterodimers with the AP-1239 motif of the HCMV MIEP. All lanes contained the
radiolabeled probe with the MIEP AP-1239 site (MIEP-239; a) or with a consensus AP-1 motif (AP-1cons; b) and in vitro-translated c-Fos, c-Jun,
or cotranslational AP-1 complex (co-Fos/Jun), except lane 1, which contained rabbit reticulocyte lysate as a control, as indicated. In addition, a
10-fold molar excess of unlabeled AP-1cons probe (b, lane 7), MIEP-239 probe (a, lane 8), a probe containing MIEP174 (c, lane 9), or a
nonspecific probe containing the NF-B site (d, lane 10) was included. The positions of the major specific nucleoprotein complexes (NPC)
corresponding to the c-Fos/c-Jun complex and of the free probe (P) are indicated. The nucleotide sequences of MIEP-239 and AP-1cons probes,
with the corresponding AP-1 motifs in boxes, are shown at the bottom of the autoradiograph. (B) The AP-1239 element of the HCMV MIEP
confers c-Fos/c-Jun-mediated responsiveness. A scheme of the reporter constructs pMIEP(66/7)CAT and pMIEP(66/7)2Ap1CAT is
shown, with the CAT gene represented by a shaded box, the location of the two copies of the AP-1239 motif inserted at the 66 site of the MIEP
marked by a black box, and their orientation indicated by arrows. Coordinates are given with respect to the HCMV ie1/ie2 transcriptional start site
(1). U373 cells were cotransfected with pMIEP(66/7)CAT or pMIEP(66/7)2Ap1CAT, along with a c-Jun, a c-Fos, or both c-Jun and c-Fos
expression vectors, and 36 h later CAT activity present in the extracts was determined. Transfection efficiency was standardized by cotransfection
of pRSV--Gal. The fold stimulation of CAT activity, calculated for each construct by taking as 1.00 the activity of the reporter gene in the absence
of c-Fos and c-Jun, is shown. Data derived from a representative CAT assay (from three independent experiments) are presented.
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was also observed (44). Thus, these results indicate that the
two AP-1 elements of the MIEP are involved in transcriptional
activation in response to TPA.
Construction of HCMVs with disruption of the AP-1 motifs
of the enhancer. To directly address whether the AP-1 motifs
within the MIEP play a role in HCMV replication, we gener-
ated two independent HCMVs bearing the AP-1 enhancer
elements disrupted. A schematic representation of the paren-
tal and mutated BAC genomes is shown in Fig. 3A. The re-
combinant HCMV BACs constructed were transfected into
HEL299 cells, and the corresponding viruses (named
HCMV.Ap1a and HCMV.Ap1b) were recovered. The integ-
rity of the recombinant HCMV genomes generated was ana-
lyzed by restriction analysis (Fig. 3B and data not shown). As
expected, the EcoRI restriction patterns of the parental and
mutated viral genomes were identical. In addition, since a
unique BglII restriction site was introduced in the MIEP when
the AP-1239 element was disrupted (shown in line 2, Fig. 3A),
we used it to confirm the successful mutagenesis of the
HCMV.Ap1 viruses. A 632-bp fragment corresponding to the
HCMV enhancer regions of HCMV and HCMV.Ap1 was am-
plified by PCR and subsequently digested with BglII. As ex-
pected, the two predicted BglII fragments of 447 and 185 bp
were detected after digestion of the PCR-amplified product
from the HCMV.Ap1 genomes, while the PCR-amplified
product from the parental virus remained unaltered after treat-
ment with this restriction enzyme (Fig. 3C). Mutations were
also corroborated by sequencing the complete enhancer and
flanking regions of the recombinant viruses (data not shown).
Altogether these results indicate that the designed modifica-
tions have been introduced within the MIEP region of the
HCMV.Ap1 mutants and that no major unwanted rearrange-
ments have occurred elsewhere in the viral genome.
Disruption of the enhancer AP-1 recognition sites does not
alter IE1 gene expression in HCMV-infected fibroblasts. Hav-
ing generated two independent HCMV.Ap1 recombinants, we
then examined the consequences of disrupting the AP-1 en-
hancer motifs for MIE gene expression in the context of the
HCMV infection in HEL299 fibroblasts. For this purpose,
HEL299 cells were infected throughout a 72-h period with
parental or mutant viruses at an MOI of 0.1, except for the 6-
and 12-h time points, in which an MOI of 0.6 was used to allow
detection of the IE1 protein, and cell lysates were subjected to
Western blot assays using a monoclonal antibody specific for
this MIE protein. As shown in Fig. 4, significant differences
could not be detected in the expression of the IE1 protein
between the HCMV and HCMV.Ap1 mutants at any of the
time points analyzed. Furthermore, treatment of cells with the
AP-1 inducer TPA (Fig. 4) did not result in differential expres-
sion of IE1 in cells infected with the mutant viruses compared
to the ones infected with the parental HCMV. Therefore, in
contrast to the results obtained in transient-transfection assays
with the isolated MIEP, abrogation of the enhancer AP-1
motifs did not significantly influence IE1 expression in infected
fibroblasts.
The AP-1 binding sites within the MIEP are not required
during HCMV replication in cultured cells in vitro. To deter-
mine the impact that disrupting the enhancer AP-1 consensus
elements has on HCMV growth, kinetic studies were per-
formed on different cell types. HEL299 fibroblasts, retinal pig-
ment epithelium (RPE) cells, and U373 MG cells derived from
glioblastoma were infected with the parental HCMV,
HCMV.Ap1a, or HCMV.Ap1b. An MOI of 0.025 was used to
infect the fully permissive fibroblasts, while RPE and U373
MG cells (which support viral replication to reduced levels
only) were infected at an MOI of 1, resulting in around 10 to
25% GFP-positive cells in the culture at 48 h p.i. Subsequently,
at different days p.i., extracellular (HEL299 and RPE) or cell-
associated (U373) infectious virus was quantified from the
cultures by standard plaque titration assays. As shown in Fig.
5A, both mutant viruses grew in a fashion comparable to that
of the parental HCMV in the three cell types tested. We next
FIG. 2. Effect of the elimination of the two enhancer AP-1 sites on MIEP activity. (A) The nucleotide sequences and locations of the two AP-1
sites lying within the MIEP enhancer are shown in shaded boxes. Below the wild-type sequence, the specific point mutations introduced in each
AP-1 element are indicated in lowercase letters. Coordinates refer to the HCMV ie1/ie2 transcriptional start site. (B) Structures of the luciferase
(Luc) reporter plasmids containing MIEP sequences from 1144 to 112 without (pMIEP.Luc) or with the AP-1239 site (pMIEPAp1239.Luc),
the AP-1239 and AP-1174 sites (pMIEPAp1239/174.Luc), or the NF-B sites (pMIEPNFkB.Luc) altered. AP-1 and NF-B recognition sites are
marked by circles and rectangles, respectively, and their positions within the MIEP are indicated. Open symbols, wild-type sequence; black symbols,
mutated sequences. (C) U937 cells were electroporated with the indicated luciferase reporter constructs along with the internal control plasmid
pRL-TK. Fifteen hours later, cells were serum starved for 24 h and then treated with TPA (20 ng/ml; ) or vehicle (DMSO; ) for 6 h. Cells were
lysed, and luciferase activity was determined. Each value represents the average 	 standard deviation of four determinations. The results are
presented as the fold induction, taking as 1.00 the activity exhibited by the cells transfected with plasmid pMIEP.Luc in the absence of TPA.
(D) Similar to the experiment shown in panel C, except that the results are presented as percentages of TPA stimulation of cells transfected with
the corresponding reporter construct relative to the activity of TPA-induced cells transfected with pMIEP.Luc (100%). (E) MEFs were transfected
with pMIEP.Luc, pMIEPAp1239/174.Luc, or pMIEPNFkB.Luc and processed as indicated for panel D. Fold induction of the pMIEP.Luc after
TPA stimulation ranged from 4 to 9 in different experiments carried out in MEFs.
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examined the phenotype exhibited by the HCMV.Ap1 mutants
under starvation conditions, by exposing cultures from 24 h
prior to infection until the end of the kinetic experiment to
medium supplemented with 0.5% FBS. Again, under these
conditions, parental and mutant viruses replicated equivalently
in HEL299 cells (Fig. 5B). Finally, we analyzed the growth
characteristics of the HCMV.Ap1 mutants after treatment with
TPA. No significant differences in the replication capacity of
HCMV.Ap1a, HCMV.Ap1b, and the parental virus were re-
vealed in HEL cells under these conditions (Fig. 5C). Alto-
gether these findings indicate that the AP-1 binding sites within
the enhancer region do not independently contribute in a sig-
nificant manner to HCMV growth in different cell types and
conditions in culture.
Generation of a chimeric hMCMV-ES containing mutations
in the AP-1 recognition sites of the HCMV enhancer. Although
the AP-1 sites within the MIEP do not seem to play a role
during HCMV replication in vitro, they could be required dur-
ing in vivo infection. We have previously established a system
for studying HCMV enhancer functions in the context of acute
and latent infections, based on the hybrid enhancer swap
hMCMV-ES virus in which the native MCMV MIEP enhancer
(sequences from 48 to 1191) has been replaced by the
HCMV enhancer (sequences from 52 to 667), and the
neonatal mouse model (26). This system allows us to directly
evaluate the role of the AP-1 binding sites present on the
HCMV enhancer during viral infection in vivo through the
generation of an hMCMV-ES with the two AP-1 binding sites
abrogated (hMCMV-ES.Ap1). hMCMV-ES.Ap1 was con-
structed using the MCMV BAC system (13, 50), and a sche-
matic representation of the parental and recombinant viral
genomes is shown in Fig. 6A (lines 1 and 2). As a control, we
generated a revertant BAC genome by restoring the HCMV
enhancer in hMCMV-ES.Ap1 (hMCMV-ES.Ap1-rev [Fig. 6A,
line 3]). The constructed viral BACs were transfected into
MEFs, and the corresponding viruses were recovered. To con-
firm that the mutated HCMV enhancer was present in the
hMCMV-ES.Ap1 virus, and taking advantage of a unique
ApaI restriction site (Fig. 6A) that was introduced in the
HCMV enhancer when the AP-1174 element was disrupted, a
FIG. 3. Construction of HCMV mutants with the AP-1 sites in the MIEP enhancer disrupted. (A) Schematic representation of the HCMV-
BAC genomes generated. The top line represents the EcoRI map of the parental HCMV-BAC genome, with the BAC region and the E-GFP gene
indicated by a gray box. The EcoRI J fragment encompassing the HCMV MIE region is enlarged below, with the structures of the ie1 and ie2
transcripts indicated. Coding and noncoding exons are depicted as black and white boxes, respectively. The crosshatched bar in line 1 represents
the MIEP enhancer (nucleotides 52 to 667 relative to the ie1/ie2 transcription start site) of the parental HCMV genome, with the AP-1 sites
indicated in white. Line 2 represents the MIEP enhancer of the HCMV.Ap1-BAC genomes with the AP-1 sites disrupted indicated in black. The
BglII restriction site introduced when mutating the MIEP AP-1 site at 239 is shown. Primers dN and dBlp, used to amplify the enhancer region,
are marked. The sizes of the PCR-amplified products from the HCMV or the HCMV.Ap1 genomes after digestion with BglII are indicated below
lines 1 and 2, respectively. The illustration is not drawn to scale. (B) Ethidium bromide-stained agarose gel of EcoRI-digested parental HCMV,
HCMV.Ap1a, and HCMV.Ap1b genomes after separation on a 0.6% agarose gel. Size markers are shown at the left. (C) Verification of the
appropriate mutagenesis of the AP-1 recognition sites within the HCMV MIEP. The enhancer sequences from the parental HCMV and mutant
HCMV.Ap1 viruses were PCR amplified using the dN and dBlp primers. Shown are the amplified products separated on a 2% agarose gel before
and after treatment with BglII. Size markers are shown at the left, and product sizes are shown at the right.
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632-bp fragment corresponding to the HCMV enhancer re-
gions of hMCMV-ES, hMCMV-ES.Ap1, and hMCMV-
ES.Ap1-rev was PCR amplified and subsequently digested with
ApaI. As expected, and shown in Fig. 6B, after treatment of
the PCR-amplified product obtained from hMCMV-ES.Ap1
with ApaI, two bands of 504 and 128 bp were detected, while
the amplified products from hMCMV-ES and hMCMV-
ES.Ap1-rev were not altered following ApaI treatment.
We next sought to analyze whether removal of the AP-1
motifs within the HCMV MIEP enhancer altered the growth
phenotype of the hMCMV-ES. To this end, we infected mouse
embryo fibroblasts (MEFs) with parental hMCMV-ES,
hMCMV-ES.Ap1, or hMCMV-ES.Ap1-rev at a low MOI. Fig-
ure 6C shows no delay in replication kinetics or reduction of
viral yields associated with hMCMV-ES.Ap1 in comparison to
the parental or revertant viruses. Furthermore, hMCMV-
ES.Ap1 and control viruses replicated in similar manners un-
der low-serum conditions and in the presence of the AP-1
inducer TPA in MEFs (Fig. 6C). To examine the growth
behavior of hMCMV-ES.Ap1 in other murine cell types (dif-
ferent than MEFs), we infected the liver-derived cell line
MMH, the endothelial cell line SVEC-4, the epithelial cell line
C127I, and the macrophagic cell line RAW 264.7 with
hMCMV-ES.Ap1 and the parental virus under low-MOI con-
ditions. As shown in Fig. 6D, no significant differences could be
detected in the replication abilities of these two viruses in any
of the different cell types tested. Thus, elimination of the AP-1
motifs within the HCMV MIEP enhancer does not result in
impaired replication kinetics in different cultured cells of
the mutant hMCMV-ES.Ap1 virus.
Growth of hMCMV-ES.Ap1 in neonatal mice. We pro-
ceeded to examine the behavior of hMCMV-ES.Ap1 in the
neonatal BALB/c mouse. We have previously shown that
hMCMV-ES is able to replicate in a variety of relevant target
organs for MCMV in this animal model, exhibiting an LD50
around 1  105 PFU (26). We first assessed the virulence level
of hMCMV-ES.Ap1 in comparison to the corresponding pa-
rental and revertant viruses. Taking into account the LD50
value reported for hMCMV-ES, we i.p. inoculated groups of
3-day-old mice with doses ranging from 1  103 to 2  106
PFU per mouse of hMCMV-ES.Ap1 or the parental or the
FIG. 4. Analysis of IE1 expression in HCMV.Ap1-infected cells.
HEL299 fibroblasts were mock infected or infected at an MOI of 0.6
(for the 6- and 12-h-p.i. time points) or 0.1 (for the 24-, 48-, and
72-h-p.i. time points) with HCMV, HCMV.Ap1a, and HCMV.Ap1b.
When indicated, cells were treated with TPA. At designated times p.i.,
cells were lysed and subjected to Western blot analysis with an HCMV
IE1-specific antibody. Anti--actin antibody was used as an internal
control.
FIG. 5. Growth kinetics of HCMV.Ap1 mutants in different cell types. (A) Cells were infected at an MOI of 0.025 (HEL299) or 1 (U373 and
RPE) with HCMV, HCMV.Ap1a, and HCMV.Ap1b. At the indicated days p.i. cultures were collected and the amounts of extracellular (HEL299
and RPE) or cell-associated (U373) infectious virus present were determined. Each data point represents the average and standard deviation of
three separate cultures. Dashed lines represent the limits of detection. (B) Similar to the experiment shown in panel A, except that HEL299 cells
were serum starved as indicated in Materials and Methods. (C) Similar to the experiment shown in panel B, except that HEL299 cells were treated
with TPA.
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revertant viruses and monitored them for their survival daily
for at least a 6-week period. As shown in Fig. 7A, the estimated
LD50s were similar for the three viruses analyzed (1.2  10
5
PFU for hMCMV-ES.Ap1, 1.6  105 PFU for hMCMV-ES,
and 1.4  105 PFU for hMCMV-ES.Ap1-rev), highlighting the
absence of a virulence alteration associated with the abolition
of the enhancer AP-1 sites in hMCMV-ES.
Next, we evaluated the growth of hMCMV-ES.Ap1 in key
target organs of MCMV. For this purpose, 3-day-old mice
were infected with 5  104 PFU of hMCMV-ES.Ap1 or
FIG. 6. Construction and in vitro growth analysis of parental hMCMV-ES, hMCMV-ES.Ap1, and hMCMV-ES.Ap1-rev viruses. (A) Schematic
illustrations of the parental hMCMV-ES, hMCMV-ES.Ap1, and hMCMV-ES.Ap1-rev genomes. The HindIII map of the parental MCMV genome
is given at the top with the BAC sequences represented by a gray box. The enlarged map below (line 1) represents the MIE locus of the
hMCMV-ES genome, carrying a 616-bp fragment (shaded rectangle) corresponding to the HCMV MIEP enhancer replacing the MCMV
enhancer, with the structure of the MIE transcripts (ie1, ie2, and ie3). Coding and noncoding exons are depicted as black and white boxes,
respectively. AP-1 sites are indicated in white. In hMCMV-ES.Ap1 (line 2), the AP-1 binding sites within the enhancer were mutated (black
circles). A unique ApaI restriction site, introduced when the MIEP AP-1174 recognition site was altered, is indicated. In hMCMV-ES.Ap1-rev
(line 3), the native HCMV enhancer sequences were reintroduced in hMCMV-ES.Ap1 in replacement of the mutated HCMV enhancer. The sizes
of the expected PCR-amplified fragments with primers dN and dBlp (marked by arrows) flanking the MIEP enhancer before and after ApaI
treatment are indicated. Coordinates are given relative to the HCMV ie1/ie2 transcription start site. The illustration is not drawn to scale. (B) To
verify the appropriate mutagenesis of the AP-1 sites, enhancer sequences were amplified from hMCMV-ES (lanes 1), hMCMV-ES.Ap1 (lanes 2),
and hMCMV-ES.Ap1-rev (lanes 3) viruses by PCR using dN and dBlp primers. The amplified products were digested with restriction enzyme ApaI.
Shown are the amplified products separated on a 2% agarose gel before and after ApaI treatment. Size markers are shown at the right, and product
sizes are shown at the left. (C) Growth kinetics of hMCMV-ES.Ap1 and control viruses in MEFs under different conditions. MEFs were infected
at an MOI of 0.025 PFU/cell with hMCMV-ES, hMCMV-ES.Ap1, and hMCMV-ES.Ap1-rev viruses in DMEM-3% FBS, under starvation
conditions (DMEM-0.5% FBS), or in the presence of TPA, as indicated. At the designated days p.i., cell supernatants were collected and titrated
on MEFs. (D) Replication of hMCMV-ES.Ap1 in different cell types. MMH cells, SVEC-4 cells, and C127I cells were infected at an MOI of 0.025,
and RAW 264.7 cells were infected at an MOI of 0.1, with hMCMV-ES and hMCMV-ES.Ap1. The level of infectious virus present in culture
supernatants at the designated days p.i. was determined. Each data point represents the average and standard deviation of three separate cultures.
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hMCMV-ES, and at days 4, 7, and 21 after infection, their
spleens, livers, kidneys, lungs, and salivary glands were ex-
tracted and examined for the presence of infectious virus.
Figure 7B shows that hMCMV-ES.Ap1 grew to levels compa-
rable and followed a course similar to those of the parental
virus. In this experiment, as a control, an MCMV bearing a
deletion of the entire enhancer region (MCMVdE [24]) was
included. Under the conditions of the experiment, infectious
MCMVdE could not be detected in any of the organs analyzed,
proving that the hMCMV-ES model has the potential to un-
ravel contributions of specific MIEP elements to viral replica-
tion during acute infection in neonates (Fig. 7B). These data
demonstrate that the AP-1 sites within the HCMV enhancer
region do not substantially contribute to hMCMV-ES growth
and virulence in the neonatal mouse.
Reactivation properties of hMCMV-ES.Ap1 in spleen and
lung explant cultures. We have also reported that hMCMV-ES
is capable of establishing latency and of reactivating in the
neonatal murine model. Therefore, we sought to examine the
reactivation properties of hMCMV-ES.Ap1 in comparison to
hMCMV-ES. Groups of 10 to 12 3-day-old mice were infected
with 5  104 PFU of hMCMV-ES.Ap1 or parental
hMCMV-ES and maintained for a minimum of 4 months. At
this time, no persistent virus could be detected in salivary gland
homogenates and viral reactivation was analyzed in spleen and
lung explants. As shown in Table 1, reactivation in spleens was
detected in 4 out of 11 (36%) animals infected with the paren-
tal virus and in 4 out of 10 (40%) animals infected with
hMCMV-ES.Ap1, while the frequency of reactivation in the
lungs was 30% and 50% for the mutant and the parental virus,
respectively. Thus, these results support the dispensability of
the AP-1 elements in the establishment of latency and subse-
quent reactivation of the hMCMV-ES.
Compensation between the AP-1 and NF-B recognition
sites of the HCMV MIEP enhancer during acute infection. A
possibility accounting for the apparently silent role of the
AP-1 sites in MIEP activation during viral infection could be
related, at least in part, to compensatory actions between
transcription factors operating in this region. In fact, con-
vergence of the NF-B and AP-1 pathways has been ob-
served in different biological systems (36). Thus, we sought
to determine whether this event was taking place by analyz-
ing the effect of inactivating the enhancer NF-B binding
sites in conjunction with the AP-1 elements on viral growth
in the in vivo model. For that purpose, hMCMV-ES.NFkB/
Ap1, having the four NF-B and two AP-1 binding sites
within the enhancer disrupted, was constructed using the
MCMV BAC system (Fig. 8A, line 4). As a control, a
revertant BAC genome was constructed by restoring
the HCMV enhancer in hMCMV-ES.NFkB/Ap1 (named
hMCMV-ES.NFkB/Ap1-rev) (Fig. 8A, line 3). The con-
structed viral BACs were transfected into MEFs, and the
corresponding viruses were recovered. For the analysis, we
also included an hMCMV-ES containing the enhancer
NF-B sites mutated (hMCMV-ES.NFkB). The original
hMCMV-ES.NFkB BAC genome is shown in Fig. 8A (line
2). To confirm that the appropriate HCMV enhancer ver-
sion was present in the recombinant viruses generated, we
took advantage of the unique ApaI and StuI restriction sites
(Fig. 8B) that were introduced in the HCMV enhancer when
the AP-1174 element was disrupted and the NF-B site at
position 101, respectively. A 500-bp fragment correspond-
FIG. 7. Infection of neonatal BALB/c mice with hMCMV-ES.Ap1,
parental, and revertant viruses. (A) Virulence of hMCMV-ES.Ap1 in
newborn mice. Groups of 4 to 11 3-day-old BALB/c mice were i.p.
inoculated with increasing doses of parental hMCMV-ES, hMCMV-
ES.Ap1, and hMCMV-ES.Ap1-rev. Animals were monitored daily for
survival, and the corresponding LD50 was calculated as indicated in
Materials and Methods. (B) Growth kinetics of hMCMV-ES.Ap1 in
the newborn mice. Three-day-old BALB/c mice were i.p. inoculated
with 5  104 PFU of hMCMV-ES, hMCMV-ES.Ap1, or MCMVdE.
Animals were sacrificed at the indicated times after infection, and viral
titers from selected organs were determined. Horizontal bars indicate
the median values. The dashed lines indicate the limit of detection of
the assay. The observed differences did not reach statistical difference
(P 
 0.05) as determined by the Mann-Whitney test (two-tailed).
TABLE 1. Reactivation of hMCMV-ES.Ap1 virusa
Virus
% reactivation in explant:
Spleen Lung
hMCMV-ES 36 (4/11) 50 (6/12)
hMCMV-ES.Ap1 40 (4/10) 30 (3/10)
a Percentages of viral reactivation from spleen and lung explants accumulated
at day 50 postexplantation. Numbers of positive mice versus the numbers of total
animals per group are shown in parentheses.
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ing to the HCMV enhancer regions of hMCMV-ES,
hMCMV-ES.NFkB, hMCMV-ES.NFkB/Ap1, and hMCMV-
ES.NFkB/Ap1-rev was PCR amplified and subsequently di-
gested with both enzymes. As expected, and shown in Fig.
8B, after digestion of the PCR-amplified products obtained
from hMCMV-ES.NFkB and hMCMV-ES.NFkB/Ap1 with
ApaI and StuI, two bands of 390 and 110 bp in the case of
hMCMV-ES.NFkB and three bands of 319, 110, and 71 bp
in the case of hMCMV-ES.NFkB/Ap1 were detected. On
the other hand, the amplified products from hMCMV-ES
and hMCMV-ES.NFkB/Ap1-rev were not altered following
ApaI and StuI treatment.
We first analyzed whether elimination of the NF-B motifs
within the HCMV MIEP enhancer altered the growth pheno-
type of the hMCMV-ES.NFkB in neonatal mice. For this pur-
pose, 3-day-old mice were inoculated with 5  104 PFU of
hMCMV-ES.NFkB or hMCMV-ES, and at days 4, 7, and 21
after infection, their spleens, livers, kidneys, lungs, and salivary
glands were removed to determine the presence of infectious
virus. Figure 9A shows no significant differences in hMCMV-
ES.NFkB replication levels and kinetics in the different mouse
organs analyzed compared with those exhibited by the parental
virus. These results indicate that, in a manner similar to that
shown for the AP-1 sites, inactivation of the NF-B recognition
sequences within the HCMV enhancer region does not result
in a perceptible impact on hMCMV-ES growth in the neonatal
mouse. We then examined the growth properties of hMCMV-
ES.NFkB/Ap1. Three-day-old mice were infected with 5 
104 PFU of hMCMV-ES.NFkB/Ap1 or control viruses
hMCMV-ES and hMCMV-ES.NFkB/Ap1-rev, and viral yields
in target organs were determined at different days after infec-
tion. Figure 9B shows an attenuated phenotype of the double
mutant hMCMV-ES.NFkB/Ap1 compared to both the
hMCMV-ES and the revertant virus. At day 4 after infection,
hMCMV-ES.NFkB/Ap1 titers in spleen, liver, kidney, and lung
were 6-, 6-, 22-, and 4-fold reduced, respectively, in comparison
to hMCMV-ES. At day 7 postinfection, a 5-, 4-, 3-, and 90-fold
decrease in spleen, liver, kidney, and lung, respectively, could also
be observed. Finally, viral titers in the salivary gland at day 14
after infection were slightly lower (2-fold) than those of the
hMCMV-ES, although this difference was not statistically signif-
icant. As expected, restoration of the natural HCMV enhancer
in the revertant hMCMV-ES.NFkB/Ap1 virus reverted the
hMCMV-ES.NFkB/Ap1 attenuated phenotype. Taking all data
together, we can conclude that the enhancer AP-1 and NF-B
binding motifs are, at least to some extent, functionally redun-
dant.
DISCUSSION
Unraveling the molecular mechanisms underlying transcrip-
tional control of the MIE region is a central issue in under-
FIG. 8. Construction of hMCMV-ES.NFkB/Ap1 and hMCMV-ES.NFkB/Ap1-rev viruses. (A) Schematic illustrations of the parental
hMCMV-ES, hMCMV-ES.NFkB, hMCMV-ES.NFkB/Ap1, and hMCMV-ES.NFkB/Ap1-rev genomes. The HindIII map of the parental
MCMV genome is given at the top with the BAC sequences represented by a gray box. The enlarged map below (line 1) represents the MIE
locus of the hMCMV-ES genome, carrying a 616-bp fragment (shaded rectangle) corresponding to the HCMV MIEP enhancer replacing the
MCMV enhancer, with the structure of the MIE transcripts (ie1, ie2, and ie3). Coding and noncoding exons are depicted as black and white
boxes, respectively. The AP-1 recognition sites within the enhancer are marked by circles, and the NF-B ones are shown as rectangles. In
hMCMV-ES.NFkB (line 2), the NF-B binding sites within the enhancer were mutated (black squares), and in hMCMV-ES.NFkB/Ap1 (line
3), both the NF-B and AP-1 sites were disrupted (black squares and circles, respectively). Unique StuI and ApaI restriction sites, introduced
when the MIEP AP-1174 and NF-B (at position 101) elements were altered, are indicated. In hMCMV-ES.NFkB/Ap1-rev (line 4), the
native HCMV enhancer sequences were reintroduced in hMCMV-ES.NFkB/Ap1 in replacement of the mutated HCMV enhancer. The sizes
of the expected PCR-amplified fragments with primers M182 and AA3 (marked by arrows) after StuI and ApaI treatment are indicated.
Coordinates are given relative to the HCMV ie1/ie2 transcription start site. The illustration is not drawn to scale. (B) To verify the
appropriate mutagenesis of the NF-B and AP-1 sites, enhancer sequences were amplified from hMCMV-ES (lanes 1), hMCMV-ES.NFkB
(lanes 2), hMCMV-ES.NFkB/Ap1 (lanes 3), and hMCMV-ES.NFkB/Ap1-rev (lanes 4) viruses by PCR using M182 and AA3 primers. The
amplified products were digested with restriction enzymes StuI and ApaI. Shown are the amplified products separated on a 2% agarose gel
before and after StuI and ApaI treatment. Size markers are shown at the left, and product sizes are shown at the right.
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standing CMV pathogenesis and latency. Thus, in an effort to
determine the functional requirements of specific signal-regu-
lated control elements of the CMV MIEP, in the present study
we have investigated the relevance of the HCMV enhancer
AP-1 recognition motifs during infection.
The transcription factor AP-1 binds and upregulates genes
containing the consensus sequence 5-TGAC/GTCA-3 (3).
Earlier reports using transient-transfection assays documented
the presence of a functional canonical AP-1 binding site
(TGACTCA) located between positions 174 and 168 (AP-
1174) of the MIEP (44). Importantly, in this study we provide
several lines of evidence to show that an additional candidate
AP-1 binding site, representing an imperfect AP-1 element
(TTAGTCA) spanning from position 239 to 233
(AP-1239), also functionally binds AP-1 and activates the
MIEP. First, mobility shift assays indicate that c-Fos and c-Jun
heterodimers form a specific DNA-bound complex with this
MIEP site at position 239. Second, we find that two copies of
this AP-1 motif are able to confer activity to a core promoter,
activity that is further increased following overexpression of
c-Fos and c-Jun. Third, we show that disruption of the en-
hancer AP-1239 motif significantly lowers (around 32%) the
overall TPA-inducible activity of the MIEP in transfection
experiments. Thus, on the basis of these results we conclude
that the nonconsensus AP-1239 element is able to bind c-Fos/
c-Jun heterodimers and is involved in the regulation of the
MIEP. Furthermore, elimination of the two AP-1 elements
resulted in a more drastic reduction (approximately 56%) of
the MIEP response to TPA. This is consistent with the results
previously reported in RAW 264.7 cells (44) when the MIEP
consensus site AP-1174 was individually disrupted, although
in this case an effect on the constitutive activation of the pro-
moter was observed, which might correlate with the different
pools of transcription factors associated with the distinct cell
types used in the two studies. Altogether, our results and pre-
vious published studies illustrate the direct involvement of the
two AP-1 sites in activation of the MIEP in transient-transfec-
tion assays.
To evaluate the functional requirements of the two AP-1
sites in the context of an infection, we engineered HCMV
recombinants in which the AP-1 sites have been eliminated. An
analysis of these recombinants in different cell systems shows
that in marked contrast with the results obtained with the
isolated promoter, loss of the two enhancer AP-1 binding sites
in HCMV does not reduce the rate of MIE gene expression or
viral replication in a variety of cell types. Thus, under the
conditions tested, the enhancer AP-1 motifs are dispensable in
the initiation and subsequent steps of the viral replication
cycle. This is in line with recent observations made by Caposio
and coworkers, showing the lack of contribution of the en-
hancer AP-1174 motif to HCMV replication in cultured fibro-
blasts (17). It is possible, however, that under specific circum-
stances, such as a shortage of specific cellular transcription
factors or strong activation of a particular signal transduction
pathway, defined elements within the MIEP could play a more
prominent role in viral replication. Indeed, Keller et al. (38)
showed that while abrogation of the enhancer ATF/CREB
elements in the HCMV MIEP failed to alter viral replication in
proliferating cells, a minimal negative effect was observed after
stimulation of the cyclic AMP (cAMP)/protein kinase A
FIG. 9. Infection of neonatal BALB/c mice with hMCMV-ES,
hMCMV-ES.NFkB, hMCMV-ES.NFkB/Ap1, and hMCMV-ES.N-
FkB/Ap1-rev. (A) Growth kinetics of hMCMV-ES.NFkB in the new-
born mice. Three-day-old BALB/c mice were i.p. inoculated with 5 
104 PFU of hMCMV-ES or hMCMV-ES.NFkB. Animals were sacri-
ficed at the indicated times after infection, and viral titers from se-
lected organs were determined. All values were above the limits of
detection of the assay (4  101 PFU/g). Horizontal bars indicate the
median values. The observed differences did not reach statistical dif-
ference (P 
 0.05) as determined by the Mann-Whitney test (two-
tailed). (B) Growth kinetics of hMCMV-ES.NFkB/Ap1 in the newborn
mice. The experiment was similar to that in panel A, except that mice
were inoculated with 5  104 PFU of hMCMV-ES, hMCMV-ES.N-
FkB/Ap1, or hMCMV-ES.NFkB/Ap1-rev. Observed differences be-
tween hMCMV-ES.NFkB/Ap1 and control viruses hMCMV-ES and
hMCMV-ES.NFkB/Ap1-rev that reached statistical differences (P 

0.05) as determined by the Mann-Whitney test (two-tailed) are indi-
cated by an asterisk.
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(PKA) signaling pathway in quiescently infected cells. Also, the
NF-B binding sites have been shown to play a neutral role
during HCMV infection of different cell types in vitro, but a
replication defect could be detected in recombinant HCMVs
derived from a clinical isolate containing the enhancer NF-B
motifs eliminated when analyzed in the absence of serum
growth factors (7, 16, 27). In this line, in a recent study, desi-
lencing of the HCMV MIE genes during HCMV quiescence in
NT-2 cells has been reported to be impaired by abrogation of
the NF-B and CREB sites (46). Our results, however, indicate
that HCMV growth is not influenced by the absence of the
enhancer AP-1 elements under starvation conditions or strong
activation of the corresponding signaling pathway by TPA. We
note that the experiments performed in the present study have
been carried out with a culture-adapted HCMV strain, pre-
venting the analysis of the derived mutants in a number of cell
types of biological significance for the virus, such as endothelial
and dendritic cells and monocytes/macrophages. Moreover,
the extreme species specificity associated with CMV restricts
the analysis of HCMV mutants in an in vivo setting. In this
respect, murine CMV has been extensively used as an animal
model system to examine different aspects of CMV biology,
pathogenesis, and latency. However, the highly repetitive na-
ture of the MCMV MIEP complicates its manipulation (19). In
addition, and as stated in the introduction, although the
MCMV and HCMV enhancers share common regulatory
pathways, their primary sequences and architectures are dis-
similar (15, 19). In an attempt to overcome these limitations,
and taking into consideration the importance of the MCMV
enhancer region during acute infection (24), recombinant
MCMVs in which the HCMV enhancer replaced the native
one were generated some years ago (4, 25, 26). Although these
enhancer swap viruses are partially attenuated in the mouse,
we have recently defined conditions of infection in neonatal
mice that result in comparable active replication of the chi-
meric virus in target organs, the establishment of latency, and
its subsequent reactivation (26). Taking advantage of this sys-
tem, we assessed the relevance of the HCMV MIEP AP-1
motifs in the context of the infection in neonatal mice by
constructing and analyzing enhancer swap viruses having the
enhancer AP-1 sites eliminated (hMCMV-ES.Ap1). We
present data that underline that inactivation of the HCMV
MIEP AP-1 sites does not result in reduced virulence or any
measurable attenuation of the hMCMV-ES in the newborn
mice. The mutant virus exhibits a replication phenotype in
different organs and dissemination properties comparable to
those of the parental virus.
The molecular mechanisms by which reactivation from la-
tency, a key hallmark of the herpesviruses, occurs remain
largely unknown. CMV reactivation is a multistep process in
which induction of MIE gene expression is a crucial checkpoint
(42). Therefore, the cellular network of transcription factors
operating through the MIEP is central in determining the
switching on of this regulatory region. In this regard, treatment
of latently infected mice with inducers of diverse signal trans-
duction pathways, such as LPS, tumor necrosis factor alpha
(TNF-), or interleukin 1 (IL-1), triggers IE expression and
MCMV reactivation in immunocompetent mice (18, 61).
Moreover, it has been postulated that as a result of the allo-
geneic stimulation and ischemia reperfusion injury associated
with organ transplantation, specific transcription factors would
get activated, including NF-B and AP-1, which in turn would
induce MIE gene expression through binding to the corre-
sponding response elements in the MIEP (30, 31). According
to this model, one could predict a relevant role of the AP-1
signaling pathway and corresponding binding sites within the
MIEP in stimulating CMV reactivation. Alternatively, AP-1
could negatively regulate MIE gene expression during latency.
We have been unable, however, to detect in our experiments a
substantial contribution of the enhancer AP-1 motifs to viral
reactivation. Thus, after inactivation of the HCMV enhancer
AP-1 elements, hMCMV-ES.Ap1 is not significantly altered in
its ability to reactivate from latency, when assessed in spleen
and lung explant cultures.
Altogether, despite the substantial involvement of the AP-1
sites in enhancing MIEP transcription in transient-transfection
assays, we have not been able to unveil a dominant function of
these elements in the viral life cycle. We cannot discard the
possibility that HCMV could use AP-1 signaling through the
enhancer region to augment its growth in vivo or increment
the efficiency of reactivation under circumstances not analyzed
here. In addition, one has to take into account that besides
components of the host transcriptional machinery, MIEP ac-
tivity is modulated by viral proteins, which might be species
specific. However, we considered the hypothesis that the en-
hancer’s insensitivity to mutations is due to its inherent robust-
ness. The absence of an overtly measurable role of the en-
hancer AP-1 motifs in the context of the infection could be
masked in part by compensation of additional cellular factors
in the enhancer that perform redundant functions. For exam-
ple, both NF-B and ATF/CREB binding activities could com-
pensate for the lack of AP-1 binding. In fact, some compensa-
tory actions in the MIEP enhancer have been recently reported
during HCMV infection in vitro (17). Here, we investigated the
potential redundancy among MIEP enhancer transcription fac-
tor binding sites, by generating an hMCMV-ES.NFkB/Ap1
containing two classes of elements in this region eliminated,
the four NF-B and two AP-1 recognition sites, and analyzing
it in the context of the neonatal mouse model. In contrast to
recombinant viruses containing each single class of element
mutated, which resulted mostly in a silent phenotype,
hMCMV-ES bearing the combined mutations showed a repli-
cation deficiency in the majority of the organs of the infected
animal examined. Thus, compensatory mechanisms may help
to explain the absence of a significant phenotype associated
with the individual disruption of either the NF-B or the AP-1
element under the experimental conditions tested. Due to the
fact that the pools of transcription factors differ among distinct
tissues and fluctuate with the various physiological conditions
encountered, HCMV may have evolved a generalistic redun-
dant enhancer that supplies transcriptional activity across
many diverse environments. The nature of this promoter also
provides an explanation for the fact that despite the variability
in the content and distribution of transcription binding sites
among enhancers from different CMV species, they all activate
transcription at equivalent high levels (63).
There is an urgent need of developing experimental in vivo
systems to study the role of the MIEP in CMV pathogenesis.
To our knowledge, this is the first time that specific genetic
elements within the HCMV MIEP enhancer have been directly
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assessed in the context of an in vivo infection. The uniqueness
of the enhancer swap MCMV-neonatal mouse system has al-
lowed us to unveil the dispensability of the HCMV enhancer
AP-1 recognition motifs during acute infection and in the pro-
cess of reactivation, and more importantly, unveil the presence
of compensatory mechanisms through the NF-B sites operat-
ing in this region. These results indicate that one may need to
simultaneously disrupt more than one host transcription factor
binding site in order to ultimately define the combination of
extracellular signal inputs, host factors, and target genetic el-
ements that dominate in the control of the MIEP.
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